For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients! The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients. This is a milestone for the carcinoid/NET community!
Read more about Novartis’ Afinitor. And CLICK HERE for further details.